Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN versus NAPROSYN.
Ibuprofen vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Clinical Note
moderateIbuprofen + Gatifloxacin
"Ibuprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateIbuprofen + Rosoxacin
"Ibuprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateIbuprofen + Levofloxacin
"Ibuprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateIbuprofen + Trovafloxacin
"Ibuprofen may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category D/X
Category C
NSAID
NSAID